5'-primary aminoalkyl psoralen compositions with platelets

US6218100A · kind A · utility

Assignee

• Cerus Corporation · US

Inventors

• Susan Wollowitz · Walnut Creek, US
• Stephen T. Isaacs · Orinda, US
• Henry Rapoport · Berkeley, US
• Hans Peter Spielmann · Lexington, US

Key dates

• Filing date: Jul 24, 1997
• Grant date: Apr 17, 2001
• Expiry date: Jul 24, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61L2/0011
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5'-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.